| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00702-005-0323-3 |
| P698 | PubMed publication ID | 15959841 |
| P2093 | author name string | W H Jost | |
| G Comes | |||
| P Roggenkämper | |||
| S Grafe | |||
| K Bihari | |||
| NT 201 Blepharospasm Study Team | |||
| P2860 | cites work | Treatment of blepharospasm with high dose brow injection of botulinum toxin | Q67270479 |
| Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm | Q69734028 | ||
| Botulinum A toxin injection as a treatment for blepharospasm | Q70069053 | ||
| Botulinum toxin type A purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force | Q71795202 | ||
| Development of resistance to botulinum toxin type A in patients with torticollis | Q72476569 | ||
| Blepharospasm: demographic and clinical survey of 250 patients | Q72578942 | ||
| Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q72884139 | ||
| Sex-related influences on the frequency and age of onset of primary dystonia. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group | Q73187430 | ||
| Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences | Q73690419 | ||
| Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers | Q80962569 | ||
| Botulinum toxin type A therapy for blepharospasm | Q24247236 | ||
| Blepharospasm: past, present, and future | Q28286195 | ||
| Blepharospasm: a review of 264 patients | Q33631310 | ||
| Pathophysiology of dystonia: a neuronal model | Q34596357 | ||
| Clinical presentation and management of antibody-induced failure of botulinum toxin therapy | Q35693989 | ||
| Pretarsal application of botulinum toxin for treatment of blepharospasm | Q36881214 | ||
| Management of spasticity associated pain with botulinum toxin A. | Q39427563 | ||
| Treatment choices of 119 patients with hemifacial spasm over 11 years | Q39463184 | ||
| Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm | Q39539908 | ||
| Botulinum toxin therapy, immunologic resistance, and problems with available materials | Q40944009 | ||
| Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 | ||
| Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study | Q44808533 | ||
| Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan | Q47199687 | ||
| Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis | Q48925163 | ||
| Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy. | Q53890860 | ||
| Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. | Q53920261 | ||
| Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathophysiological considerations. | Q64902295 | ||
| P433 | issue | 3 | |
| P921 | main subject | blepharospasm | Q883863 |
| botulinum toxin type A | Q4095199 | ||
| P304 | page(s) | 303-312 | |
| P577 | publication date | 2005-06-15 | |
| P1433 | published in | Journal of Neural Transmission | Q15750921 |
| P1476 | title | Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm | |
| P478 | volume | 113 |
| Q41879288 | 'Similar to' is not 'identical with', and 'identical with' is not 'the same as'. |
| Q35381164 | A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines |
| Q35681898 | A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins |
| Q34432824 | American academy of physical medicine and rehabilitation, 71st annual assembly. |
| Q37766794 | An update on the neurologic applications of botulinum toxins |
| Q37155202 | Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |
| Q93574950 | Author’s Reply |
| Q89172390 | Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database |
| Q82535923 | Botulinum Toxin in Facial Rejuvenation: An Update |
| Q36511588 | Botulinum neurotoxin - from laboratory to bedside |
| Q36770303 | Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia |
| Q38015772 | Botulinum toxin for the treatment of movement disorders |
| Q37974584 | Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment |
| Q35168607 | Botulinum toxin in the management of blepharospasm: current evidence and recent developments |
| Q36844729 | Botulinum toxin in the treatment of blepharospasm and hemifacial spasm |
| Q34352934 | Botulinum toxin type A products are not interchangeable: a review of the evidence |
| Q36085760 | Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice |
| Q38432422 | Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders |
| Q26824771 | Clinical relevance of botulinum toxin immunogenicity |
| Q34704553 | Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis |
| Q84654072 | Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations |
| Q82837481 | Comparing Botox and Xeomin for axillar hyperhidrosis |
| Q89273011 | Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay |
| Q48530578 | Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study |
| Q34443530 | Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? |
| Q36650003 | Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. |
| Q26766728 | Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice |
| Q30465848 | Current and future medical treatment in primary dystonia |
| Q37827385 | Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm |
| Q38084574 | Diffusion of botulinum toxins |
| Q82907926 | Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm |
| Q34612376 | Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm |
| Q34393230 | Dystonia rating scales: critique and recommendations |
| Q55013227 | Effect of the masseter muscle injection of botulinum toxin A on the mandibular bone growth of developmental rats. |
| Q36667983 | Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial. |
| Q44502462 | Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke |
| Q34037621 | Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data |
| Q36801432 | From poison to remedy: the chequered history of botulinum toxin |
| Q36844148 | Future aspects of botulinum neurotoxins |
| Q93124762 | Glucose hypometabolism in the visual cortex proportional to disease severity in patients with essential blepharospasm |
| Q38046142 | Immunogenicity of botulinum toxins |
| Q55483517 | Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience. |
| Q60933941 | IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study |
| Q37129916 | Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia |
| Q91370858 | Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia |
| Q85041978 | Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay |
| Q36223269 | Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays |
| Q33935194 | Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm |
| Q43185582 | Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products |
| Q98176897 | Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites |
| Q36171693 | Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement |
| Q35050218 | Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm |
| Q37340491 | Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity |
| Q42378237 | Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products |
| Q37811268 | Review and Update of Involuntary Facial Movement Disorders Presenting in the Ophthalmological Setting |
| Q49225454 | Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm |
| Q37115101 | Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm |
| Q38058730 | The pharmacological management of post-stroke muscle spasticity |
| Q28268360 | Treatment of dystonia |
| Q30566734 | Treatment of dystonia. |
| Q48616189 | Treatment of focal dystonia |
| Q64982276 | Use of botulinum toxin for movement disorders. |
| Q84577943 | [Does dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella lines] |
| Q82750420 | [Essential blepharospasm : Practice-oriented therapy with botulinum toxin employing reduced treatment intervals] |
| Q84301833 | [Pharmacology of botulinum toxin drugs] |
| Q83901620 | [Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique] |
Search more.